CB Insights Blog Inside the AI drug discovery arms race: Record M&A activity, a biologics funding spree, and more

This is the first report in a 3-part series on how AI is reshaping discovery, pre-clinical, and clinical research in drug R&D. Bringing a drug to market traditionally involves staggering costs — averaging $1.3B when accounting for all failed compounds … The post Inside the AI drug discovery arms race: Record M&A activity, a biologics funding spree, and more appeared first on CB Insights Research.